307 related articles for article (PubMed ID: 24002601)
1. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Shpilberg O; Jackisch C
Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
[TBL] [Abstract][Full Text] [Related]
2. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
3. ENHANZE
Locke KW; Maneval DC; LaBarre MJ
Drug Deliv; 2019 Dec; 26(1):98-106. PubMed ID: 30744432
[TBL] [Abstract][Full Text] [Related]
4. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
Styles IK; Feeney OM; Nguyen TH; Brundel DHS; Kang DW; Clift R; McIntosh MP; Porter CJH
J Control Release; 2019 Dec; 315():85-96. PubMed ID: 31655131
[TBL] [Abstract][Full Text] [Related]
5. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.
Bittner B; Richter WF; Hourcade-Potelleret F; McIntyre C; Herting F; Zepeda ML; Schmidt J
Arzneimittelforschung; 2012 Sep; 62(9):401-9. PubMed ID: 22918857
[TBL] [Abstract][Full Text] [Related]
6. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
Harb G; Lebel F; Battikha J; Thackara JW
Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Dolton MJ; Chesterman A; Moein A; Sink KM; Waitz A; Blondeau K; Kerchner GA; Hu N; Brooks L; Wetzel-Smith MK; Roden A; Deshmukh A; Peng K; Carrasco-Triguero M; Smith J; Ostrowitzki S; Quartino A
Clin Pharmacol Ther; 2021 Nov; 110(5):1337-1348. PubMed ID: 34347883
[TBL] [Abstract][Full Text] [Related]
9. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
[TBL] [Abstract][Full Text] [Related]
11. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
12. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
13. Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.
Rosengren S; Dychter SS; Printz MA; Huang L; Schiff RI; Schwarz HP; McVey JK; Drake FH; Maneval DC; Kennard DA; Frost GI; Sugarman BJ; Muchmore DB
AAPS J; 2015 Sep; 17(5):1144-56. PubMed ID: 25967925
[TBL] [Abstract][Full Text] [Related]
14. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
[TBL] [Abstract][Full Text] [Related]
15. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
[TBL] [Abstract][Full Text] [Related]
16. Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.
Knowles SP; Printz MA; Kang DW; LaBarre MJ; Tannenbaum RP
Expert Opin Drug Deliv; 2021 Nov; 18(11):1673-1685. PubMed ID: 34585991
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.
Printz MA; Dychter SS; DeNoia EP; Harrigan R; Sugarman BJ; Zepeda M; Souratha J; Kang DW; Maneval DC
Curr Ther Res Clin Exp; 2020; 93():100604. PubMed ID: 32963641
[TBL] [Abstract][Full Text] [Related]
18. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
Thomas JR; Yocum RC; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]